Michael Thomas Heffernan - 10 Feb 2025 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting relationship: Director
Issuer ticker: COLL
Reported as of: 10 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Feb 2025, 16:10:53 UTC
Prior SEC filing: 14 Jun 2024
Next SEC filing: 26 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Shirley R. Kuhlmann as Attorney-in-Fact for Michael T. Heffernan

Key filing fact

Michael Thomas Heffernan filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 12 Feb 2025.

Key facts

This page summarizes Michael Thomas Heffernan's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2025, 16:10.

Change

Previous filing in this sequence was filed on 14 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COLL transaction

Common Stock

Award

Transaction value: $0
Shares: +4,820
Change %: +11%
Price: $0.000000
Shares after: 50,328
Date: 10 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.